Stocks · News reference
Filed: 2026-08-10 AccNo: 0001213900-26-086933 Size: 270 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-24 AccNo: 0001213900-26-093021 Size: 300 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgarhttps://www.sec.gov/Archives/edgar/data/907654/000121390026092612/ea0301041-s3_oruka.htm
Read original at benzingaGuggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Read original at benzingaBTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
Read original at benzinga